CenterPoint Energy (CNP) Q3 2026 Earnings Call Transcript

CenterPoint Energy reported Q3 2026 non-GAAP EPS of $0.53 and raised 2026 guidance to $1.90–$1.92; it initiated 2027 guidance of $2.07–$2.09, representing 9% growth at the midpoint. The company increased its 10-year capital plan by $4 billion to $70.7 billion through 2035 and accelerated $1.5 billion of projects, with enterprise rate base CAGR projected above 14% through 2030. Management expects annual EPS growth of 7%–9% through 2035, while citing higher interest rates as a sector headwind and planning $500 million–$700 million of common equity issuance in 2027.

Analysis

The bullish case is less about the size of the capex plan than whether CenterPoint can convert queued demand into billable, recoverable assets without stretching its balance sheet. Existing trackers and brownfield work could shorten cash-recovery delays, but neither makes proposed load bankable: customer commitments, deposits, credit quality, and actual energization matter more than submitted gigawatts. Hyperscalers’ need for power may strengthen utility negotiating leverage; it also makes project timing and customer concentration more consequential.

Near term, the December ERCOT audit is the key sentiment test. Over 1–3 months, evidence that the remaining baseload queue is firm and that 2027 investment is on schedule would support the growth premium; withdrawals or delays would expose the gap between rate-base growth and EPS growth. The 2027 common issuance is a real offset to growth, while higher rates pressure a long-duration utility multiple. Over 6–18 months, the 765-kV filing and further transmission-study updates could expand the opportunity, but greenfield routes bring greater permitting and community risk than brownfield upgrades. The claimed affordability benefit is also politically important: if bills rise faster than customer growth can dilute fixed costs, regulators may constrain recovery.

Contrarian read: the 14% rate-base trajectory is not equivalent to 14% shareholder earnings growth; management’s lower EPS-growth range and prospective dilution are the relevant underwriting anchors. There is no basis here to trade Moody’s Corporation (MCO): its inclusion reflects the credit-metric reference, not a company-specific catalyst. Valuation and current share performance are not supplied, so avoid an unconditional outright long.

Key Decisions for Investors

• Watch the December 10 ERCOT audit before adding CNP exposure. Treat material attrition from the baseload queue, or delayed customer commitments, as a thesis warning; verify signed agreements and load milestones rather than relying on submitted demand.
• Conditional relative-value idea: if the audit supports the firm-load case and CNP does not already trade at a material premium to regulated-utility peers, consider long CNP / short XLU to express company-specific load and rate-base execution while partly hedging sector rate sensitivity. Reassess on the audit result; exit or reduce if load confirmation weakens or financing needs rise beyond guidance.
• Track 2027 equity issuance, FFO-to-debt, and tracker recovery alongside capex. A worsening credit cushion or equity needs above the stated plan would undermine EPS conversion even if rate base expands; stronger cash recovery or proceeds from temporary-generation assets could improve the funding profile.
• Keep MCO on no-trade status absent evidence of a distinct Moody’s-specific earnings or outlook catalyst; a reference to Moody’s credit methodology does not establish an investment signal.